CXCR2 and nasopharyngeal carcinoma: To explore whether the CXCR2 inhibitor SB225002 has a direct effect on NPC cells, we treated a panel of 5 established NPC cell lines with various concentrations of SB2250002 for 24, 48, and 72 h and assayed cell viability by CCK8 assay.